Ergenoğlu Mete Ahmet, Yeniel Ahmet Özgür, Akdoğan Ayşin, Göker Ege Nazan Tavmergen, Tavmergen Erol
Department of Gynecology and Obstetrics, Faculty of Medicine, Ege University, İzmir, Turkey.
Family Planning and Infertility Research and Treatment Center, Ege University, İzmir, Turkey.
J Turk Ger Gynecol Assoc. 2012 Jun 1;13(2):91-7. doi: 10.5152/jtgga.2012.10. eCollection 2012.
To determine serum and follicular leptin levels in patients using gonadotropin releasing hormone agonist and antagonist in Assisted Reproductive Technology short protocol cycles and to evaluate pregnancy outcomes.
Patients randomly selected to join assisted reproductive technology cycles during February 2004-July 2004 were enrolled in this study. Group 1 consisted of 21 patients receiving r FSH+ GnRH agonists, whereas Group 2 consisted of 34 patients who received r FSH +GnRH antagonists. During the ovulation induction period 5 serum samples were collected (induction day 1, day 3 or antagonist starting day, human chorionic hormone day, oocyte pickup day, and twelfth day of embryo transfer). Follicular fluid samples were collected to be evaluated for leptin, estradiol, prolactin and luteinizing hormone.
There was no difference in age, basal FSH, basal LH, and basal E2 between groups. Serum leptin levels were similar in both groups. Also, when each group's serum leptin levels were evaluated according to the presence of pregnancy, there was no significant difference in both groups. When follicle leptin levels were evaluated according to the existence of pregnancy, in both groups the follicle leptin levels were lower in pregnant participants but this difference was not statistically significant. When obesity is defined as body mass index over 26.5, there is a correlation between obesity and leptin levels in Group 2.
Our results have shown that both agonists and antagonists have similar efficacy and effect in poor responder women. Leptin levels in either groups, whether pregnant or non-pregnant were not statistically different. This result shows the need for more studies on leptin in infertility.
测定辅助生殖技术短方案周期中使用促性腺激素释放激素激动剂和拮抗剂患者的血清及卵泡液瘦素水平,并评估妊娠结局。
选取2004年2月至2004年7月期间随机入选辅助生殖技术周期的患者。第1组由21例接受重组促卵泡素(rFSH)+促性腺激素释放激素激动剂的患者组成,而第2组由34例接受rFSH +促性腺激素释放激素拮抗剂的患者组成。在促排卵期间收集5份血清样本(促排卵第1天、第3天或拮抗剂开始日、人绒毛膜促性腺激素日、取卵日以及胚胎移植第12天)。收集卵泡液样本以评估瘦素、雌二醇、催乳素和促黄体生成素水平。
两组患者在年龄、基础促卵泡素(FSH)、基础促黄体生成素(LH)和基础雌二醇(E2)方面无差异。两组血清瘦素水平相似。此外,当根据妊娠情况评估每组血清瘦素水平时,两组均无显著差异。当根据妊娠情况评估卵泡瘦素水平时,两组中妊娠患者的卵泡瘦素水平均较低,但这种差异无统计学意义。当将肥胖定义为体重指数超过26.5时,第2组中肥胖与瘦素水平之间存在相关性。
我们的结果表明,激动剂和拮抗剂在反应不良的女性中具有相似的疗效和作用。无论妊娠与否,两组中的瘦素水平在统计学上均无差异。这一结果表明需要对不孕症中的瘦素进行更多研究。